Clinical trials
Completed Takayasu Arteritis trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
29 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2006 | 1 |
| 2008 | 2 |
| 2010 | 3 |
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 3 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 3 |
| 2019 | 1 |
| 2020 | 1 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 29 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| University of South Florida | 5 |
| University of Pennsylvania | 3 |
| Instituto Nacional de Cardiologia Ignacio Chavez | 2 |
| Liu Tian | 2 |
| Peking Union Medical College Hospital | 2 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| Chinese SLE Treatment And Research Group | 1 |
| French Cardiology Society | 1 |
| Groupe français d'étude des Maladies Inflammatoires de loeil | 1 |
| Hospital of Southern Norway Trust | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Takayasu Arteritis | 29 |
| Giant Cell Arteritis | 10 |
| Granulomatosis with Polyangiitis | 8 |
| Behcet Syndrome | 7 |
| Microscopic Polyangiitis | 7 |
| Polyarteritis Nodosa | 7 |
| Churg-Strauss Syndrome | 6 |
| Vasculitis | 6 |
| IgA Vasculitis | 5 |
| Vasculitis, Central Nervous System | 5 |
Trials
Showing 26 to 29 of 29. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.